Valeant's 'sales force disruption' puts the hurt on Xifaxan sales - FiercePharma
FiercePharmaValeant's 'sales force disruption' puts the hurt on Xifaxan salesFiercePharmaXifaxan isn't the only one of Valeant's products that's underperforming.
Valeant missed huge on its 'billion dollar' savior drug — that should raise a big red flag - Business Insider
Business InsiderValeant missed huge on its 'billion dollar' savior drug — that should raise a big red flagBusiness InsiderOn February 1, 2013, Salix received a subpoena from the U.
Valeant's Latest Punch in the Gut: Patent Challenge on Xifaxan - Wall Street Journal (blog)
Wall Street Journal (blog)Valeant's Latest Punch in the Gut: Patent Challenge on XifaxanWall Street Journal (blog)The executives at Valeant Pharmaceuticals International are fighting a war on multiple sides.
Super Bowl 50: Xifaxan Ad - Wall Street Journal
Wall Street JournalSuper Bowl 50: Xifaxan AdWall Street JournalIrritable Bowel Syndrome can ruin the fan experience, as seen in this Super Bowl ad for Xifaxan.
Valeant CEO blames salesforce turnover for disappointing Xifaxan sales - Medical Marketing and Media
Medical Marketing and MediaValeant CEO blames salesforce turnover for disappointing Xifaxan salesMedical Marketing and MediaPapa attributed less-than-stellar sales of its best-selling brand to “significant sales turnover,” as a result of its integration with Salix Pharmaceuticals, which developed Xifaxan and was acquired by Valeant in March 2015.